ShanXi C&Y Pharmaceutical Group Co.,LTD.

Equities

300254

CNE1000016D0

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-13 pm EDT 5-day change 1st Jan Change
9.47 CNY +3.72% Intraday chart for ShanXi C&Y Pharmaceutical Group Co.,LTD. -1.56% -1.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 184.999997 million in funding CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. announced that it expects to receive CNY 105 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd. CI
C&Y Pharmaceutical Raises $15.5 Million in Private Placement MT
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it has received CNY 109.999995 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 130 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. and Chen Jinsong entered into an equity transfer agreement to acquire 15.43% stake in Sichuan C&Y Traditional Chinese Medicine Co., Ltd. from Chen Renhu and Tang Wenjing. CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Hangzhou Pollen Group Company Limited announced that it has received CNY 115 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd. CI
Shenzhen Purcotton Technology Co. Ltd announced that it expects to receive CNY 80 million in funding from ShanXi C&Y Pharmaceutical Group Co., LTD. CI
Shenzhen PureH2B Technology Co., Ltd. announced that it expects to receive CNY 100 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd. CI
Hangzhou Pollen Group Company Limited announced that it expects to receive CNY 115 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd. CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
ShanXi C&Y Pharmaceutical Group Co., LTD. announced that it has received CNY 139.999998 million in funding CI
Chart ShanXi C&Y Pharmaceutical Group Co.,LTD.
More charts
ShanXi C&Y Pharmaceutical Group Co., Ltd. is principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Company’s main products include anti-infective agents, respiratory system agents, cardiovascular drugs, antidepressant drugs, urinary system agents, pediatric agents and other drugs, as well as pharmaceutical raw materials and pharmaceutical intermediates. It also involves in the manufacture and distribution of health food products, as well as the provision of deoxyribonucleic acid (DNA) genetic preservation and pregnant environment testing services. The Company distributes its products in domestic market.
More about the company
  1. Stock Market
  2. Equities
  3. 300254 Stock
  4. News ShanXi C&Y Pharmaceutical Group Co.,LTD.
  5. C&Y Pharmaceutical Raises $15.5 Million in Private Placement
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW